• Chelsea Therapeutics International Ltd., of Charlotte, N.C., disclosed plans to reduce head count "significantly," retaining only employees needed to pursue FDA approval of Northera (droxidopa) for symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure.